Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. - Berger, P.; Scotto-Gomez, E.; Molimard, M.; Marthan, R.; Le Gros, V.; Tunon-de-Lara, J. M. (Allergy, 2007)